Hazard-rate analysis in state I malignant melanoma
- 1 September 1986
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 122 (9) , 999-1002
- https://doi.org/10.1001/archderm.122.9.999
Abstract
Hazard-rate analysis provides a unique means of assessing prognosis in patients with malignant disease. The hazard rate is the probability of a patient dying within a particular unit of time after definitive therapy. Hazard-rate analysis was performed on a series of 719 consecutive patients with clinical stage I cutaneous malignant melanoma (MM). The peak hazard rate for death from metastatic MM occurred during the 48th month of follow-up. Thereafter, the hazard rate declined and approached zero by the 120th month. When the patients were stratified by the thickness of their primary MM, thicker lesions reached their peak hazard-rate month earlier than thinner lesions. We conclude that after 120-month survival, the risk of dying from MM is virtually zero. However, since rare late deaths from MM occur, lifetime follow-up is recommended.This publication has 9 references indexed in Scilit:
- Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP updateCancer, 1983
- Prognostic parameters in recurrent malignant melanomaCancer, 1983
- Late Recurrence of Cutaneous MelanomaArchives of Surgery, 1983
- Small-Cell Carcinoma of Lung: Reinduction Therapy After Late RelapseAnnals of Internal Medicine, 1983
- Can patients with breast cancer be cured of their disease? A sample of the M. D. Anderson hospital experienceCancer, 1983
- PREDICTIVE VALUE OF REGRESSION RATES FOLLOWING CHEMOTHERAPY OF SMALL CELL-CARCINOMA OF THE LUNG1983
- A MULTIVARIATE-ANALYSIS OF PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA1982
- Spontaneous regression of primary malignant melanomas with regional metastasesCancer, 1965
- OBSERVATIONS ON NATURAL COURSE OF SKIN CANCER1965